Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 5/20 | 0.43 |
| ▸ | CA1 | P00915 | 4/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.43 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.43 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 2/20 | 0.38 |
| ▸ | MMP9 | P14780 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1201139 | 1.00 | KMT2A (0.46) | KMT2APOLBCA2CA1FOLH1 | |
| SCHEMBL5322259 | 0.92 | KMT2A (0.43) | KMT2APOLBCA2CA1FOLH1 | |
| SCHEMBL5322256 | 0.92 | KMT2A (0.43) | KMT2APOLBCA2CA1FOLH1 | |
| SCHEMBL24390546 | 0.87 | KMT2A (0.46) | KMT2APOLBCA2CA1FOLH1 | |
| SCHEMBL24390487 | 0.87 | KMT2A (0.46) | KMT2APOLBCA2CA1FOLH1 | |
| SCHEMBL21841510 | 0.83 | CA2 (0.41) | KMT2APOLBCA2CA1FOLH1 | |
| SCHEMBL16478816 | 0.81 | FOLH1 (0.51) | KMT2APOLBFOLH1MEN1 | |
| SCHEMBL9716584 | 0.79 | FOLH1 (0.49) | FOLH1LMNATDP1 | |
| SCHEMBL9716721 | 0.79 | FOLH1 (0.49) | FOLH1LMNATDP1 | |
| SCHEMBL9716589 | 0.79 | FOLH1 (0.49) | FOLH1LMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7888351-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-02-15 | — | — | US | disclosed |
| US-20110034462-A1 | ORGANIC COMPOUNDS | BAESCHLIN DANIEL KASPAR | 2011-02-10 | — | — | US | disclosed |
| US-20090281069-A1 | ORGANIC COMPOUNDS | BAESCHLIN DANIEL KASPAR | 2009-11-12 | — | — | US | disclosed |
| EP-2007723-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007115821-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281069-A1 | ORGANIC COMPOUNDS | OTC, OAT, SLCO2B1 | KMT2A 2877/4885POLB 933/4885CA2 621/4885 |
| US-20110034462-A1 | ORGANIC COMPOUNDS | OTC, OAT, SLCO2B1 | KMT2A 2877/4885POLB 933/4885CA2 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.